Bausch Health Sign LOI with the Pan-Canadian Pharmaceutical Alliance for Acne Vulgaris Medication

Bausch Health, Canada is pleased to announce that on August 29, 2022, it signed a letter of intent (LOI) with the Pan-Canadian Pharmaceutical Alliance (pCPA) for Arazlo (tazarotene) indicated for the topical treatment of acne vulgaris in patients 10 years of age and older.

This was rapidly followed by the formulary addition of Arazlo with the Non-Insured Health Benefits (NIHB), the Ontario Drug Benefit Formulary, the Alberta Drug Benefit List, and the Saskatchewan Formulary effective respectively October 24, 2022, October 31, 2022, and November 01, 2022.

Bausch Health, Canada continues to collaborate with all other participating jurisdictions to accelerate formulary listing additions and maximize patient access in Canada.

Acne vulgaris is a skin condition that begins with the formation of a plug in the hair follicles. The plug is made up of surface skin, oil, and bacteria. It is seen as a whitehead or blackhead (comedones). After the formation of the plug, oil in the gland escapes into the surrounding skin and causes inflammation which is seen as papules, pustules, or cysts.

Manufactured in Canada, ARAZLO works by helping the normal growth of the skin cells (keratinocytes) and reducing skin inflammation in acne. These recent public reimbursement listing agreements are an important step in helping provide new dermatology treatment options for Canadian patients.

Source: Bausch Health